| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy, and
2 Sigma-Tau, Pomezia, Rome, Italy
Requests for reprints: Graziella Pratesi, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-02-23902626; Fax: 39-02-23902692. E-mail: graziella.pratesi{at}istitutotumori.mi.it
ST1481 (gimatecan) is a novel lipophilic camptothecin with a promising preclinical pharmacological profile. On the basis of its high antitumor efficacy when delivered by the oral route, the compound is suitable for prolonged administration. This schedule of treatment has been reported as the most appropriate to exploit the antiangiogenic effects of cytotoxic drugs. The aim of the study was to investigate the antiangiogenic and antitumor effects of oral ST1481 in human tumor xenografts. In spite of a marginal drug effect against the s.c. growing A549 lung carcinoma following administration with an intermittent schedule (q4dx4 times, maximum tolerated dose: 2 mg/kg), tumor growth was strongly inhibited by a daily low-dose (0.5 mg/kg) prolonged administration. Immunohistochemical analysis showed a reduced number of microvessels in tumors of both treated groups versus controls and a significantly higher reduction in the daily versus the q4dx4-treated tumors (P < 0.0001, by Student's t test). In our experimental model, the relation between microvessel density and tumor size (r = 0.738, by the Spearman rank test) suggests a role of inhibition of tumor vasculature in tumor response. Significant inhibition of tumor angiogenesis (P < 0.0001 versus control tumors) was observed even with a very low drug dose (0.06 mg/kg) in the orthotopically implanted (i.d.) MeWo melanoma, under conditions causing minimal tumor growth inhibition. Additional evidences of the antiangiogenic activity of ST1481 were provided by antimotility effects on endothelial cells, in vivo inhibition of vascularization in the Matrigel assay, and down-regulation of the expression of the proangiogenic basic fibroblast growth factor in A549 tumor cells associated with inhibition of the pathway involving Akt. In conclusion, the available results support the possibility that the antiangiogenic properties of ST1481 contribute to its antitumor potential and that this effect might be enhanced by the continuous low-dose treatment.
This article has been cited by other articles:
|
|
 |
|
  R. Supino, G. Petrangolini, G. Pratesi, M. Tortoreto, E. Favini, L. D. Bo, P. Casalini, E. Radaelli, A. C. Croce, G. Bottiroli, et al. Antimetastatic Effect of a Small-Molecule Vacuolar H+-ATPase Inhibitor in in Vitro and in Vivo Preclinical Studies J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro-oncol, July 1, 2007; 9(3): 354 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer Ther., April 1, 2006; 5(4): 962 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Calvani, A. Rapisarda, B. Uranchimeg, R. H. Shoemaker, and G. Melillo Hypoxic induction of an HIF-1{alpha}-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells Blood, April 1, 2006; 107(7): 2705 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. De Cesare, G. Pratesi, S. Veneroni, R. Bergottini, and F. Zunino Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7357 - 7364. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
